Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Prognosis of ovarian cancer in women with type 2 diabetes using metformin and other forms of antidiabetic medication or statins: a retrospective cohort study.

Urpilainen E, Marttila M, Hautakoski A, Arffman M, Sund R, Ilanne-Parikka P, Arima R, Kangaskokko J, Puistola U, Hinkula M, Läärä E.

BMC Cancer. 2018 Jul 28;18(1):767. doi: 10.1186/s12885-018-4676-z.

2.

Antidiabetic Medication, Statins and the Risk and Prognosis of Non-endometrioid Endometrial Cancer in Women with Type 2 Diabetes.

Arima R, Marttila M, Hautakoski A, Arffman M, Sund R, Ilanne-Parikka P, Kangaskokko J, Urpilainen E, Läärä E, Hinkula M, Puistola U.

Anticancer Res. 2018 Jul;38(7):4169-4178. doi: 10.21873/anticanres.12710.

PMID:
29970546
3.

The role of metformin and statins in the incidence of epithelial ovarian cancer in type 2 diabetes: a cohort and nested case-control study.

Urpilainen E, Marttila M, Hautakoski A, Arffman M, Sund R, Ilanne-Parikka P, Arima R, Kangaskokko J, Puistola U, Läärä E, Hinkula M.

BJOG. 2018 Jul;125(8):1001-1008. doi: 10.1111/1471-0528.15151. Epub 2018 Mar 12.

4.

Cause-specific mortality in endometrioid endometrial cancer patients with type 2 diabetes using metformin or other types of antidiabetic medication.

Arima R, Hautakoski A, Marttila M, Arffman M, Sund R, Ilanne-Parikka P, Kangaskokko J, Hinkula M, Puistola U, Läärä E.

Gynecol Oncol. 2017 Dec;147(3):678-683. doi: 10.1016/j.ygyno.2017.10.014. Epub 2017 Oct 18.

PMID:
29054569
5.

Antidiabetic medication, statins and the risk of endometrioid endometrial cancer in patients with type 2 diabetes.

Arima R, Marttila M, Hautakoski A, Arffman M, Sund R, Ilanne-Parikka P, Kangaskokko J, Läärä E, Puistola U, Hinkula M.

Gynecol Oncol. 2017 Sep;146(3):636-641. doi: 10.1016/j.ygyno.2017.06.011. Epub 2017 Jun 20.

PMID:
28645427
6.

Indolepropionic acid and novel lipid metabolites are associated with a lower risk of type 2 diabetes in the Finnish Diabetes Prevention Study.

de Mello VD, Paananen J, Lindström J, Lankinen MA, Shi L, Kuusisto J, Pihlajamäki J, Auriola S, Lehtonen M, Rolandsson O, Bergdahl IA, Nordin E, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Landberg R, Eriksson JG, Tuomilehto J, Hanhineva K, Uusitupa M.

Sci Rep. 2017 Apr 11;7:46337. doi: 10.1038/srep46337.

7.

Association of Long-Term Dietary Fat Intake, Exercise, and Weight with Later Cognitive Function in the Finnish Diabetes Prevention Study.

Lehtisalo J, Lindström J, Ngandu T, Kivipelto M, Ahtiluoto S, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Eriksson JG, Uusitupa M, Tuomilehto J, Luchsinger J; Finnish Diabetes Prevention Study.

J Nutr Health Aging. 2016 Feb;20(2):146-54. doi: 10.1007/s12603-015-0565-1.

PMID:
26812510
8.

Diabetes, glycaemia, and cognition-a secondary analysis of the Finnish Diabetes Prevention Study.

Lehtisalo J, Lindström J, Ngandu T, Kivipelto M, Ahtiluoto S, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Eriksson JG, Uusitupa M, Tuomilehto J, Luchsinger JA; Finnish Diabetes Prevention Study (DPS).

Diabetes Metab Res Rev. 2016 Jan;32(1):102-10. doi: 10.1002/dmrr.2679. Epub 2015 Aug 18.

PMID:
26172529
9.

Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study.

de Mello VD, Lindström J, Eriksson JG, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Pihlajamäki J, Tuomilehto J, Uusitupa M.

Nutr Metab Cardiovasc Dis. 2015 Jul;25(7):635-42. doi: 10.1016/j.numecd.2015.03.012. Epub 2015 Mar 28.

PMID:
25921846
10.

Cognition in the Finnish diabetes prevention study.

Luchsinger JA, Lehtisalo J, Lindström J, Ngandu T, Kivipelto M, Ahtiluoto S, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Eriksson JG, Uusitupa M, Tuomilehto J; Finnish Diabetes Prevention Study (DPS).

Diabetes Res Clin Pract. 2015 Jun;108(3):e63-6. doi: 10.1016/j.diabres.2015.02.023. Epub 2015 Feb 26.

PMID:
25799080
11.

The association between HbA1c, fasting glucose, 1-hour glucose and 2-hour glucose during an oral glucose tolerance test and cardiovascular disease in individuals with elevated risk for diabetes.

Lind M, Tuomilehto J, Uusitupa M, Nerman O, Eriksson J, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Peltonen M, Pivodic A, Lindström J.

PLoS One. 2014 Oct 6;9(10):e109506. doi: 10.1371/journal.pone.0109506. eCollection 2014.

12.

Monitoring the use of lipid-lowering medication among persons with newly diagnosed diabetes: a nationwide register-based study.

Vehko T, Sund R, Arffman M, Manderbacka K, Ilanne-Parikka P, Keskimäki I.

BMJ Open. 2013 Nov 4;3(11):e003414. doi: 10.1136/bmjopen-2013-003414.

13.

Increased cancer mortality in diabetic people treated with insulin: a register-based follow-up study.

Forssas E, Sund R, Manderbacka K, Arffman M, Ilanne-Parikka P, Keskimäki I.

BMC Health Serv Res. 2013 Jul 9;13:267. doi: 10.1186/1472-6963-13-267.

14.

Importance of weight loss maintenance and risk prediction in the prevention of type 2 diabetes: analysis of European Diabetes Prevention Study RCT.

Penn L, White M, Lindström J, den Boer AT, Blaak E, Eriksson JG, Feskens E, Ilanne-Parikka P, Keinänen-Kiukaanniemi SM, Walker M, Mathers JC, Uusitupa M, Tuomilehto J.

PLoS One. 2013;8(2):e57143. doi: 10.1371/journal.pone.0057143. Epub 2013 Feb 25.

15.

Improved lifestyle and decreased diabetes risk over 13 years: long-term follow-up of the randomised Finnish Diabetes Prevention Study (DPS).

Lindström J, Peltonen M, Eriksson JG, Ilanne-Parikka P, Aunola S, Keinänen-Kiukaanniemi S, Uusitupa M, Tuomilehto J; Finnish Diabetes Prevention Study (DPS).

Diabetologia. 2013 Feb;56(2):284-93. doi: 10.1007/s00125-012-2752-5. Epub 2012 Oct 24.

PMID:
23093136
16.

Leukocyte telomere length in the Finnish Diabetes Prevention Study.

Hovatta I, de Mello VD, Kananen L, Lindström J, Eriksson JG, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Peltonen M, Tuomilehto J, Uusitupa M.

PLoS One. 2012;7(4):e34948. doi: 10.1371/journal.pone.0034948. Epub 2012 Apr 6.

17.

Insulin secretion and its determinants in the progression of impaired glucose tolerance to type 2 diabetes in impaired glucose-tolerant individuals: the Finnish Diabetes Prevention Study.

de Mello VD, Lindström J, Eriksson J, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Sundvall J, Laakso M, Tuomilehto J, Uusitupa M.

Diabetes Care. 2012 Feb;35(2):211-7. doi: 10.2337/dc11-1272. Epub 2011 Dec 30.

18.

Association of ADIPOR2 gene variants with cardiovascular disease and type 2 diabetes risk in individuals with impaired glucose tolerance: the Finnish Diabetes Prevention Study.

Siitonen N, Pulkkinen L, Lindström J, Kolehmainen M, Schwab U, Eriksson JG, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Tuomilehto J, Uusitupa M.

Cardiovasc Diabetol. 2011 Sep 24;10:83. doi: 10.1186/1475-2840-10-83.

19.

Cardiovascular autonomic dysfunction is associated with central obesity in persons with impaired glucose tolerance.

Laitinen T, Lindström J, Eriksson J, Ilanne-Parikka P, Aunola S, Keinänen-Kiukaanniemi S, Tuomilehto J, Uusitupa M.

Diabet Med. 2011 Jun;28(6):699-704. doi: 10.1111/j.1464-5491.2011.03278.x.

PMID:
21388444
20.

Association of ADIPOQ gene variants with body weight, type 2 diabetes and serum adiponectin concentrations: the Finnish Diabetes Prevention Study.

Siitonen N, Pulkkinen L, Lindström J, Kolehmainen M, Eriksson JG, Venojärvi M, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Tuomilehto J, Uusitupa M.

BMC Med Genet. 2011 Jan 10;12:5. doi: 10.1186/1471-2350-12-5.

21.

HbA(1c) in diagnosing and predicting Type 2 diabetes in impaired glucose tolerance: the Finnish Diabetes Prevention Study.

Pajunen P, Peltonen M, Eriksson JG, Ilanne-Parikka P, Aunola S, Keinänen-Kiukaanniemi S, Uusitupa M, Tuomilehto J, Lindström J; Finnish Diabetes Prevention Study.

Diabet Med. 2011 Jan;28(1):36-42. doi: 10.1111/j.1464-5491.2010.03183.x.

PMID:
21166843
22.

Impact of positive family history and genetic risk variants on the incidence of diabetes: the Finnish Diabetes Prevention Study.

Uusitupa MI, Stancáková A, Peltonen M, Eriksson JG, Lindström J, Aunola S, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Tuomilehto J, Laakso M.

Diabetes Care. 2011 Feb;34(2):418-23. doi: 10.2337/dc10-1013. Epub 2010 Oct 27.

23.

Leisure-time physical activity and the metabolic syndrome in the Finnish diabetes prevention study.

Ilanne-Parikka P, Laaksonen DE, Eriksson JG, Lakka TA, Lindstr J, Peltonen M, Aunola S, Keinánen-Kiukaanniemi S, Uusitupa M, Tuomilehto J; Finnish Diabetes Prevention Study Group.

Diabetes Care. 2010 Jul;33(7):1610-7. doi: 10.2337/dc09-2155. Epub 2010 Apr 22.

24.

Association of the FTO gene variant (rs9939609) with cardiovascular disease in men with abnormal glucose metabolism--the Finnish Diabetes Prevention Study.

Lappalainen T, Kolehmainen M, Schwab US, Tolppanen AM, Stančáková A, Lindström J, Eriksson JG, Keinänen-Kiukaanniemi S, Aunola S, Ilanne-Parikka P, Herder C, Koenig W, Gylling H, Kolb H, Tuomilehto J, Kuusisto J, Uusitupa M; Finnish Diabetes Prevention Study Group.

Nutr Metab Cardiovasc Dis. 2011 Sep;21(9):691-8. doi: 10.1016/j.numecd.2010.01.006. Epub 2010 Apr 18.

PMID:
20400278
25.

Variation in the UCP2 and UCP3 genes associates with abdominal obesity and serum lipids: the Finnish Diabetes Prevention Study.

Salopuro T, Pulkkinen L, Lindström J, Kolehmainen M, Tolppanen AM, Eriksson JG, Valle TT, Aunola S, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Tuomilehto J, Laakso M, Uusitupa M.

BMC Med Genet. 2009 Sep 21;10:94. doi: 10.1186/1471-2350-10-94.

26.

Sleep duration, lifestyle intervention, and incidence of type 2 diabetes in impaired glucose tolerance: The Finnish Diabetes Prevention Study.

Tuomilehto H, Peltonen M, Partinen M, Lavigne G, Eriksson JG, Herder C, Aunola S, Keinänen-Kiukaanniemi S, Ilanne-Parikka P, Uusitupa M, Tuomilehto J, Lindström J; Finnish Diabetes Prevention Study Group.

Diabetes Care. 2009 Nov;32(11):1965-71. doi: 10.2337/dc08-1980. Epub 2009 Aug 3.

27.

Educational attainment and effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study.

Wikström K, Peltonen M, Eriksson JG, Aunola S, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Uusitupa M, Tuomilehto J, Lindström J.

Diabetes Res Clin Pract. 2009 Oct;86(1):e1-5. doi: 10.1016/j.diabres.2009.06.014. Epub 2009 Jul 10.

PMID:
19592125
28.

Ten-year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study--secondary analysis of the randomized trial.

Uusitupa M, Peltonen M, Lindström J, Aunola S, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Valle TT, Eriksson JG, Tuomilehto J; Finnish Diabetes Prevention Study Group.

PLoS One. 2009 May 21;4(5):e5656. doi: 10.1371/journal.pone.0005656.

29.

Anti-inflammatory effect of lifestyle changes in the Finnish Diabetes Prevention Study.

Herder C, Peltonen M, Koenig W, Sütfels K, Lindström J, Martin S, Ilanne-Parikka P, Eriksson JG, Aunola S, Keinänen-Kiukaanniemi S, Valle TT, Uusitupa M, Kolb H, Tuomilehto J; Finnish Diabetes Prevention Study Group.

Diabetologia. 2009 Mar;52(3):433-42. doi: 10.1007/s00125-008-1243-1. Epub 2009 Jan 8.

PMID:
19130041
30.

Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study.

Lindström J, Peltonen M, Eriksson JG, Aunola S, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Uusitupa M, Tuomilehto J; Finnish Diabetes Prevention Study (DPS) Group.

Diabetes Care. 2008 May;31(5):857-62. doi: 10.2337/dc07-2162. Epub 2008 Feb 5.

PMID:
18252900
31.

Interaction of single nucleotide polymorphisms in ADRB2, ADRB3, TNF, IL6, IGF1R, LIPC, LEPR, and GHRL with physical activity on the risk of type 2 diabetes mellitus and changes in characteristics of the metabolic syndrome: The Finnish Diabetes Prevention Study.

Kilpeläinen TO, Lakka TA, Laaksonen DE, Mager U, Salopuro T, Kubaszek A, Todorova B, Laukkanen O, Lindström J, Eriksson JG, Hämäläinen H, Aunola S, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Tuomilehto J, Laakso M, Uusitupa M; Finnish Diabetes Prevention Study Group.

Metabolism. 2008 Mar;57(3):428-36. doi: 10.1016/j.metabol.2007.10.022.

PMID:
18249219
32.

Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study.

Ilanne-Parikka P, Eriksson JG, Lindström J, Peltonen M, Aunola S, Hämäläinen H, Keinänen-Kiukaanniemi S, Laakso M, Valle TT, Lahtela J, Uusitupa M, Tuomilehto J; Finnish Diabetes Prevention Study Group.

Diabetes Care. 2008 Apr;31(4):805-7. doi: 10.2337/dc07-1117. Epub 2008 Jan 9.

PMID:
18184907
33.

SNPs in PPARG associate with type 2 diabetes and interact with physical activity.

Kilpeläinen TO, Lakka TA, Laaksonen DE, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Lindi V, Tuomilehto J, Uusitupa M, Laakso M.

Med Sci Sports Exerc. 2008 Jan;40(1):25-33.

PMID:
18091023
34.

Physical activity modifies the effect of SNPs in the SLC2A2 (GLUT2) and ABCC8 (SUR1) genes on the risk of developing type 2 diabetes.

Kilpeläinen TO, Lakka TA, Laaksonen DE, Laukkanen O, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Aunola S, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Tuomilehto J, Uusitupa M, Laakso M; Finnish Diabetes Prevention Study Group.

Physiol Genomics. 2007 Oct 22;31(2):264-72. Epub 2007 Jul 17. Erratum in: Physiol Genomics. 2008 Feb 19;32(3):419.

PMID:
17636114
35.

Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study.

Lindström J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemiö K, Hämäläinen H, Härkönen P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Mannelin M, Paturi M, Sundvall J, Valle TT, Uusitupa M, Tuomilehto J; Finnish Diabetes Prevention Study Group.

Lancet. 2006 Nov 11;368(9548):1673-9.

PMID:
17098085
36.

Association between ghrelin gene variations and blood pressure in subjects with impaired glucose tolerance.

Mager U, Kolehmainen M, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Tuomilehto JO, Pulkkinen L, Uusitupa MI; Finnish Diabetes Prevention Study Group.

Am J Hypertens. 2006 Sep;19(9):920-6.

PMID:
16942934
37.

Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study.

Herder C, Peltonen M, Koenig W, Kräft I, Müller-Scholze S, Martin S, Lakka T, Ilanne-Parikka P, Eriksson JG, Hämäläinen H, Keinänen-Kiukaanniemi S, Valle TT, Uusitupa M, Lindström J, Kolb H, Tuomilehto J.

Diabetes. 2006 Aug;55(8):2340-6.

38.

Association of the Leu72Met polymorphism of the ghrelin gene with the risk of Type 2 diabetes in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study.

Mager U, Lindi V, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Tuomilehto J, Laakso M, Pulkkinen L, Uusitupa M; Finnish Diabetes Prevention Study Group.

Diabet Med. 2006 Jun;23(6):685-9.

PMID:
16759313
39.

Association of sequence variations in the gene encoding adiponectin receptor 1 (ADIPOR1) with body size and insulin levels. The Finnish Diabetes Prevention Study.

Siitonen N, Pulkkinen L, Mager U, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Tuomilehto J, Laakso M, Uusitupa M.

Diabetologia. 2006 Aug;49(8):1795-805. Epub 2006 May 25.

PMID:
16724230
40.

Serum uric acid as a harbinger of metabolic outcome in subjects with impaired glucose tolerance: the Finnish Diabetes Prevention Study.

Niskanen L, Laaksonen DE, Lindström J, Eriksson JG, Keinänen-Kiukaanniemi S, Ilanne-Parikka P, Aunola S, Hämäläinen H, Tuomilehto J, Uusitupa M.

Diabetes Care. 2006 Mar;29(3):709-11. No abstract available.

PMID:
16505534
41.

Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study.

Hämäläinen H, Rönnemaa T, Virtanen A, Lindström J, Eriksson JG, Valle TT, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Rastas M, Aunola S, Uusitupa M, Tuomilehto J; Finnish Diabetes Prevention Study Group.

Diabetologia. 2005 Nov;48(11):2248-53. Epub 2005 Oct 5.

PMID:
16205886
42.

Genetic variation in leptin receptor gene is associated with type 2 diabetes and body weight: The Finnish Diabetes Prevention Study.

Salopuro T, Pulkkinen L, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Tuomilehto J, Laakso M, Uusitupa M; Finnish Diabetes Prevention Study Group.

Int J Obes (Lond). 2005 Oct;29(10):1245-51.

PMID:
15997246
43.

Polymorphisms in the SLC2A2 (GLUT2) gene are associated with the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study.

Laukkanen O, Lindström J, Eriksson J, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Tuomilehto J, Uusitupa M, Laakso M; Finnish Diabetes Prevention Study.

Diabetes. 2005 Jul;54(7):2256-60.

44.

Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study.

Laaksonen DE, Lindström J, Lakka TA, Eriksson JG, Niskanen L, Wikström K, Aunola S, Keinänen-Kiukaanniemi S, Laakso M, Valle TT, Ilanne-Parikka P, Louheranta A, Hämäläinen H, Rastas M, Salminen V, Cepaitis Z, Hakumäki M, Kaikkonen H, Härkönen P, Sundvall J, Tuomilehto J, Uusitupa M; Finnish diabetes prevention study.

Diabetes. 2005 Jan;54(1):158-65.

45.

Polymorphisms of the SUR1 (ABCC8) and Kir6.2 (KCNJ11) genes predict the conversion from impaired glucose tolerance to type 2 diabetes. The Finnish Diabetes Prevention Study.

Laukkanen O, Pihlajamäki J, Lindström J, Eriksson J, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Tuomilehto J, Uusitupa M, Laakso M; Finnish Diabetes Prevention Study Group.

J Clin Endocrinol Metab. 2004 Dec;89(12):6286-90.

PMID:
15579791
46.

Common variants in beta2- and beta3-adrenergic receptor genes and uncoupling protein 1 as predictors of the risk for type 2 diabetes and body weight changes. The Finnish Diabetes Prevention Study.

Salopuro T, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Tuomilehto J, Laakso M, Uusitupa M.

Clin Genet. 2004 Oct;66(4):365-7. No abstract available.

PMID:
15355441
47.

Prevalence of the metabolic syndrome and its components: findings from a Finnish general population sample and the Diabetes Prevention Study cohort.

Ilanne-Parikka P, Eriksson JG, Lindström J, Hämäläinen H, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Mannelin M, Rastas M, Salminen V, Aunola S, Sundvall J, Valle T, Lahtela J, Uusitupa M, Tuomilehto J; Finnish Diabetes Prevention Study Group.

Diabetes Care. 2004 Sep;27(9):2135-40.

PMID:
15333474
48.

Association between a deletion/insertion polymorphism in the alpha2B-adrenergic receptor gene and insulin secretion and Type 2 diabetes. The Finnish Diabetes Prevention Study.

Siitonen N, Lindström J, Eriksson J, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Tuomilehto J, Laakso M, Uusitupa M.

Diabetologia. 2004 Aug;47(8):1416-24. Epub 2004 Jul 28.

PMID:
15309292
49.

Common polymorphisms in the genes regulating the early insulin signalling pathway: effects on weight change and the conversion from impaired glucose tolerance to Type 2 diabetes. The Finnish Diabetes Prevention Study.

Laukkanen O, Pihlajamäki J, Lindström J, Eriksson J, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Tuomilehto J, Uusitupa M, Laakso M; Finnish Diabetes Prevention Study Group.

Diabetologia. 2004 May;47(5):871-7. Epub 2004 May 1.

PMID:
15127203
50.

The G-250A promoter polymorphism of the hepatic lipase gene predicts the conversion from impaired glucose tolerance to type 2 diabetes mellitus: the Finnish Diabetes Prevention Study.

Todorova B, Kubaszek A, Pihlajamäki J, Lindström J, Eriksson J, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Tuomilehto J, Uusitupa M, Laakso M; Finnish Diabetes Prevention Study.

J Clin Endocrinol Metab. 2004 May;89(5):2019-23.

PMID:
15126514

Supplemental Content

Loading ...
Support Center